Trailhead Biosystems key facts
as of Oct 2026- Developer of iPSC-derived research cell products and differentiation technologies designed to enable consistent and scalable human cell models.
- Trailhead Biosystems is valued at approximately $38.6M as of Oct 2026 (last reported valuation).
- It has raised $61.6M across 4 recorded rounds; the latest was Early Stage VC ($20.0M) in Jun 2024.
- Notable investors include Ohio Department of Development, MAK Capital, Advanced Regenerative Manufacturing Institute, Global Cardiovascular Innovation Center, Innovation Fund America — 6 tracked in total.
- Trailhead Biosystems has filed 7 Form Ds with the SEC since 2020, most recently May 2025 ($20.0M sold to 2 investors).
- Status: Privately Held (backing).
Trailhead Biosystems's last reported valuation, Nov 2023. Nothing priced has surfaced since.
- ·Watch Trailhead Biosystems: the Monday email on marks, rounds and moves
Trailhead Biosystems funding rounds
4 roundsTrailhead Biosystems valuation
Trailhead Biosystems's last reported valuation was $38.6 million in Nov 2023. No priced round, secondary trade or fund mark has surfaced since.
How much has Trailhead Biosystems raised?
Trailhead Biosystems has raised $61.6 million across 4 recorded rounds since 2020. The largest was a $10 million early-stage round in Sep 2022; the most recent was a $20 million early-stage round in Jun 2024.
Trailhead Biosystems has filed 7 Form Ds with the SEC since 2020, most recently in May 2025 ($20 million sold to 2 investors).
Trailhead Biosystems investors
6 investors are on record for Trailhead Biosystems, including Ohio Department of Development, MAK Capital, Advanced Regenerative Manufacturing Institute and Global Cardiovascular Innovation Center. The early-stage round in Jun 2024 drew 4 investors.
About Trailhead Biosystems
Developer of iPSC-derived research cell products and differentiation technologies designed to enable consistent and scalable human cell models. The company offers ready-to-use cell products, custom differentiation services, and a high-dimensional design-of-experiments platform integrating computational modeling, automation, and large-scale data generation, enabling researchers and drug developers to achieve reproducible, high-purity cell differentiation and accelerate disease modeling and preclinical research.
- Sector
- Healthcare
- HQ
- Beachwood, OH, United States
- Founded
- 2015
- Employees
- 49
- Website
- trailbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.